Navigation Links
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Date:8/4/2009

d June 30, 2009 was $13.0 million compared to revenue of $20.4 million in the second quarter of 2008. Revenue for the first half of 2009 was $22.7 million as compared to revenue of $40.4 million in the first half of 2008. This decrease in revenue is primarily the result of lower contract research and manufacturing revenues resulting from the sale of certain of the company's pulmonary assets to Novartis which occurred on December 31, 2008.

Cash, cash equivalents, and short-term investments at June 30, 2009 were $294.3 million.

Conference Call to Discuss Second Quarter 2009 Financial Results

A conference call to review results will be held on August 4, 2009 at 2 PM Pacific Time.

Details are below:

Howard Robin, president and chief executive officer, and John Nicholson, chief financial officer, will host a conference call beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) on Tuesday, August 4, 2009.

        To access the conference call, follow these instructions:

        Dial: (866) 831-6270 (U.S.); (617) 213-8858 (international)
        Passcode: 25099763 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, August 19, 2009 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 26851386.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics to address unmet medical needs by leveraging
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Inc. (NYSE: PFE ) today announced ... Innovation, an entrepreneurial network of partnerships with leading ... by accessing leading translational researchers.  The University of ... the network. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
... 16, 2010 Baxa Corporation , a leading ... operations, today announced significant upgrades to its DoseEdge ... workflow management tool that verifies the use of correct ... chemo, TPN and oral liquid doses.  This release includes ...
Cached Medicine Technology:Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 2Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 3Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 4Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 2Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 3Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 4
(Date:8/29/2014)... The Department of Health and Human Services (HHS) ... today allowing healthcare providers to attest for Meaningful Use ... (CEHRT) or a combination of the 2011 and 2014 ... able to fully implement 2014 Edition CEHRT for a ... use 2011 Edition CEHRT, or a combination of 2011/2014 ...
(Date:8/29/2014)... Los Angeles, CA (PRWEB) August 29, 2014 ... has announced his plan to rename his practice to ... US Hair Restoration has served the needs of hair ... clients who traveled to its centers in Los Angeles, ... results through surgical and non surgical treatments, many of ...
(Date:8/29/2014)... 30, 2014 UWDress.com, one of the ... its latest collection of 2014 floor length bridesmaid ... for these wonderful items. According to the company’s marketing ... a greatly discounted rate (up to 60 percent off) ... products has a special neckline: strapless, one-shoulder, bateau and ...
(Date:8/29/2014)... 2014 As reported by GantDaily.com in the ... Abuse Trends , Outbreaks (8/20), the National Institute on Drug ... drug abuse trends by turning to social media. As NIDA ... it is also working with the University of Maryland to ... Warning System, which will be funded by the National Institute ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
Breaking Medicine News(10 mins):Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... Based on findings of a recent study researchers say eating ... Researchers say they have found a correlation between high consumption ... hot dogs, and lunch meats like ham, salami and bologna, ... study, nearly 149,000 meat eaters between ages 50 and 74 ...
... part of the body’s immune system and help protect ... A new study shows promising treatment for acute myelogenous ... natural killer cells from a patient’s family member. ... the highly fatal cancer of the bone marrow that ...
... study researchers say autistic boys with language problems might have ... disorder known as Specific Language Impairment (SLI) // and they ... and how to choose the best treatments for individual components ... at Broca’s area -- a key language center in the ...
... as a man’s disease, but recent reports suggest it ... is helping to identify which women are at highest ... records of nearly 2,400 women taking part in the ... heart disease are about three-times more likely to develop ...
... New research shows that people who have implanted ... safely use magnetic resonance imaging .// ,Pacemakers ... regulate an abnormal heartbeat known as arrhythmia. Researchers ... of the MRI may heat up metal components ...
... gene known as “mighty mouse” might be beneficial in ... a German neurologist , stumbled // on a newborn who ... child had a mutation in his myostatin gene that effectively ... known to regulate muscle growth. So far the child, now ...
Cached Medicine News:
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... is the first microplate spectrophotometer designed specifically ... days per week. With rugged hardware, proven ... breaks the barrier of traditional spectrophotometry to ... instrument can easily read up to eight, ...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
Medicine Products: